Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: A brief history of stavudine (D4T) and its comparison with other dideoxynucleosides

Antiviral Research

Volumn 85, Issue 1, 2010, Pages 34-38

  Martin, John C ^a   Hitchcock, Michael J M ^a   De Clercq, Erik ^b   Prusoff, William H ^c  

^a GILEAD SCIENCES   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; AZT; D4C; D4T; ddC; ddI; FLT; Nucleoside analogues

Indexed keywords

2',3' DIDEHYDRO 2',3' DIDEOXYCYTIDINE; 2',3' DIDEOXYADENOSINE; 3' FLUOROTHYMIDINE; DIDANOSINE; IDOXURIDINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; VALACICLOVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CYTOPENIA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENTERIC COATED TABLET; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LACTIC ACIDOSIS; LETHALITY; LIPODYSTROPHY; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

DIDEOXYNUCLEOSIDES; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; UNITED STATES;

EID: 73549122138     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.10.006     Document Type: Review

References (62)

1. Ahluwalia G., Cooney D.A., Mitsuya H., Fridland A., Flora K.P., Hao Z., Dalal M., Broder S., and Johns D.G. Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem. Pharmacol. 36 (1987) 3797-3800
2. Anderson R.E., Dunkle L.M., Smaldone L., Adler M., Wirtz C., Kriesel D., Cross A., and Martin R.R. Design and implementation of the stavudine parallel-track program. J. Infect. Dis. 171 Suppl. 2 (1995) S118-S122
3. August E.M., Marongiu M.E., Lin T.-S., and Prusoff W.H. Initial studies on the cellular pharmacology of 3′-deoxythymidine-2′-ene (d4T): a potent and selective inhibitor of human immunodeficiency virus. Biochem. Pharmacol. 37 (1988) 4419-4422
4. Baba M., Pauwels R., Herdewijn P., De Clercq E., Desmyter J., and Vandeputte M. Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem. Biophys. Res. Commun. 142 (1987) 128-134
5. Balzarini J., Pauwels R., Herdewijn P., De Clercq E., Cooney D.A., Kang G.-J., Dalal M., Johns D.G., and Broder S. Potent and selective anti-HTLV-III/LAV activity of 2′,3′-dideoxycytidinene, the 2′,3′-unsaturated derivative of 2′,3′-dideoxycytidine. Biochem. Biophys. Res. Commun. 140 (1986) 735-742
6. Balzarini J., Kang G.-J., Dalal M., Herdewijn P., De Clercq E., Broder S., and Johns D.G. The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2′,3′-didehydro-2′,3′-dideoxyribonucleosides: a comparison with their parental 2′,3′-dideoxyribonucleosides. Mol. Pharmacol. 32 (1987) 162-167
7. Balzarini J., Baba M., Pauwels R., Herdewijn P., and De Clercq E. Anti-retrovirus activity of 3′-fluoro- and 3′-azido-substituted pyrimidine 2′,3′-dideoxynucleoside analogues. Biochem. Pharmacol. 37 (1988) 2847-2856
8. Balzarini J., Herdewijn P., and De Clercq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 264 (1989) 6127-6133
9. Bazin H., Chattopadhyaya J., Datema R., Ericson A.-C., Gilljam G., Johansson N.G., Hansen J., Koshida R., Moelling K., Oberg B., Remaud G., Stening G., Vrang L., Wahren B., and Wu J.C. An analysis of the inhibition of replication of HIV and MuLV by some 3′-blocked pyrimidine analogs. Biochem. Pharmacol. 38 (1989) 109-119
10. Berenguer J., González J., Ribera E., Domingo P., Santos J., Miralles P., Ribas M.A., Asensi V., Gimeno J.L., Pérez-Molina J.A., Terrón J.A., Santamaría J.M., and Pedrol E. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Clin. Infect. Dis. 47 (2008) 1083-1092
11. Brinkman K., Smeitink J.A., Romijn J.A., and Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354 (1999) 1112-1115
12. Chen C.-H., and Cheng Y.-C. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J. Biol. Chem. 264 (1989) 11934-11937
13. Chen C.-H., Vazquez-Padua M., and Cheng Y.-C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol. Pharmacol. 39 (1991) 625-628
14. Colla L., De Clercq E., Busson R., and Vanderhaeghe H. Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]. J. Med. Chem. 26 (1983) 602-604
15. Cooley T.P., Kunches L.M., Saunders C.A., Ritter J.K., Christopher M.A., Perkins C.J., McLaren C., McCaffrey R.P., and Liebman H.A. Once-daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: results of a phase I trial. N. Engl. J. Med. 322 (1990) 1340-1345
16. De Clercq E., Descamps J., De Somer P., and Holý A. (S)-9-(2,3-Dihydroxypropyl)adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity. Science 200 (1978) 563-565
17. Dieterich D.T. Long-term complications of nucleoside reverse transcriptase inhibitor therapy. AIDS Read. 13 (2003) 176-187
18. Dudley M.N., Graham K.K., Kaul S., Geletko S., Dunkle L., Browne M., and Mayer K. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J. Infect. Dis. 166 (1992) 480-485
19. Farina V., and Benigni D.A. A new synthesis of 2′,3′-dideoxynucleosides for AIDS chemotherapy. Tetrahedron Lett. 29 (1988) 1239-1242
20. Fischl M.A., Richman D.D., Grieco M.H., Gottlieb M.S., Volberding P.A., Laskin O.L., Leedom J.M., Groopman J.E., Mildvan D., Schooley R.T., Jackson G.G., Durack D.T., and King D. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317 (1987) 185-191
21. Furman P.A., Fyfe J.A., St. Clair M.H., Weinhold K., Rideout J.L., Freeman G.A., Lehrman S.N., Bolognesi D.P., Broder S., Mitsuya H., and Barry D.W. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 8333-8337
22. Gallant J.E., Staszewski S., Pozniak A.L., DeJesus E., Suleiman J.M.A.H., Miller M.D., Coakley D.F., Lu B., Toole J.J., and Cheng A.K. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. J. Am. Med. Assoc. 292 (2004) 191-201
23. Hamamoto Y., Nakashima H., Matsui T., Matsuda A., Ueda T., and Yamamoto N. Inhibitory effect of 2′,3′-didehydro-2′,3′-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus. Antimicrob. Agents Chemother. 31 (1987) 907-910
24. Hartmann H., Vogt M.W., Durno A.G., Hirsch M.S., Hunsmann G., and Eckstein F. Enhanced in vitro inhibition of HIV-1 replication by 3′-fluoro-3′-deoxythymidine compared to several other nucleoside analogs. AIDS Res. Hum. Retroviruses 4 (1988) 457-466
25. Herdewijn P., Balzarini J., De Clercq E., Pauwels R., Baba M., Broder S., and Vanderhaeghe H. 3′-Substituted 2′,3′-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents. J. Med. Chem. 30 (1987) 1270-1278
26. Ho H.-T., and Hitchcock M.J.M. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine: a nucleoside analog active against human immunodeficiency virus. Antimicrob. Agents Chemother. 33 (1989) 844-849
27. Hochster H., Dieterich D., Bozzette S., Reichman R.C., Connor J.D., Leibes L., Sonke R.L., Spector S.A., Valentine F., Pettinelli C., and Richman D.D. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. Ann. Intern. Med. 113 (1990) 111-117
28. Horwitz J.P., Chua J., and Noel M. Nucleosides V the monomesylates of 1-(2′-deoxy-beta-d-lyxofuranosyl)thymine. J. Org. Chem. 29 (1964) 2076-2078
29. Horwitz J.P., Chua J., Da Rooge M.A., Noel M., and Klundt I.L. Nucleosides. IX. The formation of 2′,3′-unsaturated pyrimidine nucleosides via a novel beta-elimination reaction. J. Org. Chem. 31 (1966) 205-211
30. Horwitz J.P., Chua J., Noel M., and Donatti J.T. Nucleosides. XI. 2′,3′-Dideoxycytidine. J. Org. Chem. 32 (1967) 817-818
31. Kawaguchi T., Fukushima S., Ohmura M., Mishima M., and Nakano M. Enzymatic and chemical stability of 2′,3′-dideoxy-2′,3′-didehydropyrimidine nucleosides: potential anti-acquired immunodeficiency syndrome agents. Chem. Pharm. Bull. (Tokyo) 37 (1989) 1944-1945
32. Lambert J.S., Seidlin M., Reichman R.C., Plank C.S., Laverty M., Morse G.D., Knupp C., McLaren C., Pettinelli C., Valentine F.T., and Dolin R. 2′,3′-Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: a phase I trial. N. Engl. J. Med. 322 (1990) 1333-1340
33. Larder B.A., Darby G., and Richman D.D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243 (1989) 1731-1734
34. Lin T.-S., Chen M.S., McLaren C., Gao Y.-S., Ghazzouli I., and Prusoff W.H. Synthesis and antiviral activity of various 3′-azido, 3′-amino, 2′,3′-unsaturated and 2′,3′-dideoxy analogues of pyrimidine deoxyribonucleosides against retroviruses. J. Med. Chem. 30 (1987) 440-444
35. Lin T.-S., Schinazi R.F., and Prusoff W.H. Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene (3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus. Biochem. Pharmacol. 36 (1987) 2713-2718
36. Lin T.-S., Schinazi R.F., Chen M.S., Kinney-Thomas E., and Prusoff W.H. Antiviral activity of 2′,3′-dideoxycytidin-2′-ene (2′,3′-dideoxy-2′,3′-didehydrocytidine) against human immunodeficiency virus in vitro. Biochem. Pharmacol. 36 (1987) 311-316
37. Lin, T.-S., Prusoff, W.H., 1990, December 18. Use of 3′-deoxythymidin-2′-ene (3′-deoxy-2′,3′-didehydrothymidine) in treating patients infected with retroviruses. U.S. Patent 4,978,655.
38. Lindblad G., Jonsson G., and Falk J. Adenine toxicity: a three week intravenous study in dogs. Acta Pharmacol. Toxicol. 32 (1973) 246-256
39. Mansuri M.M., Starrett Jr. J.E., Ghazzouli I., Hitchcock M.J.M., Sterzycki R.Z., Brankovan V., Lin T.-S., August E.M., Prusoff W.H., Sommadossi J.-P., and Martin J.C. 1-(2,3-Dideoxy-beta-d-glycero-pent-2-enofuranosyl)thymine. A highly potent and selective anti-HIV agent. J. Med. Chem. 32 (1989) 461-466
40. Mansuri M.M., Starrett Jr. J.E., Wos J.A., Tortolani D.R., Brodfuehrer P.R., Howell H.G., and Martin J.C. Preparation of 1-(2,3-dideoxy-beta-d-glycero-pent-2-enofuranosyl)thymine (d4T) and 2′,3′-dideoxyadenosine (ddA): general methods for the synthesis of 2′,3′-olefinic and 2′,3′-dideoxy nucleoside analogues active against HIV. J. Org. Chem. 54 (1989) 4780-4785
41. Mansuri M.M., Hitchcock M.J.M., Buroker R.A., Bregman C.L., Ghazzouli I., Desiderio J.V., Starrett J.E., Sterzycki R.Z., and Martin J.C. Comparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immunodeficiency virus. Antimicrob. Agents Chemother. 34 (1990) 637-641
42. Mansuri M.M., Farina V., Starrett Jr. J.E., Benigni D.A., Brankovan V., and Martin J.C. Preparation of the geometric isomers of DDC, DDA, D4C and D4T as potential anti-HIV agents. Bioorgan. Med. Chem. Lett. 1 (1991) 65-68
43. Martin J.C., Dvorak C.A., Smee D.F., Matthews T.R., and Verheyden J.P.H. 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J. Med. Chem. 26 (1983) 759-761
44. Martin J.C., Hitchcock M.J.M., Fridland A., Ghazzouli I., Kaul S., Dunkle L.M., Sterzycki R.Z., and Mansuri M.M. Comparative studies of 2′,3′-didehydro-2′,3′-dideoxythymidine (D4T) with other pyrimidine nucleoside analogues. Ann. New York Acad. Sci. (1990) 22-28
45. Matthes E., Lehmann C., Scholz D., Rosenthal H.A., and Langen P. Phosphorylation, anti-HIV activity and cytotoxicity of 3′-fluorothymidine. Biochem. Biophys. Res. Commun. 153 (1988) 825-831
46. McLaren C., Datema R., Knupp C.A., and Buroker R.A. Review: didanosine. Antiviral Chem. Chemother. 2 (1991) 321-328
47. Mitsuya H., Popovic M., Yarchoan R., Matsushita S., Gallo R.C., and Broder S. Suranim protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 226 (1984) 172-174
48. Mitsuya H., Weinhold K.J., Furman P.A., St. Clair M.H., Lehrman S.N., Gallo R.C., Bolognesi D., Barry D.W., and Broder S. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-asssociated virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 7096-7100
49. Mitsuya H., and Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 1911-1915
50. Petersen E.A., Ramirez-Ronda C.H., Hardy W.D., Schwartz R., Sacks H.S., Follansbee S., Peterson D.M., Cross A., Anderson R.E., and Dunkle L.M. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J. Infect. Dis. 171 Suppl. 2 (1995) S131-S139
51. Prisbe E.J., and Martin J.C. A novel and efficient preparation of 2′,3′-dideoxynucleosides. Synth. Commun. 15 (1985) 401-409
52. Prusoff W.H. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim. Biophys. Acta 32 (1959) 295-296
53. Richman D.D., Fischl M.A., Grieco M.H., Gottlieb M.S., Volberding P.A., Laskin O.L., Leedom J.M., Groopman J.E., Mildvan D., Hirsch M.S., Jackson G.G., Durack D.T., and Nusinoff-Lehrman S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317 (1987) 192-197
54. Russell J.W., Whiterock V.J., Marrero D., and Klunk L.J. Pharmacokinetics of a new anti-HIV agent: 2′,3′-dideoxy-2′,3′-didehydrothymidine (d4T). Nucleosides Nucleotides 8 (1989) 845-848
55. Saag M.S., Cahn P., Raffi F., Wolff M., Pearce D., Molina J.-M., Powderly W., Shaw A.L., Mondou E., Hinkle J., Borroto-Esoda K., Quinn J.B., Barry D.W., and Rousseau F. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naïve patients: a randomized trial. J. Am. Med. Assoc. 292 (2004) 180-189
56. Sommadossi J.-P., and Carlisle R. Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob. Agents Chemother. 31 (1987) 452-454
57. Spruance S.L., Pavia A.T., Mellors J.W., Murphy R., Gathe Jr. J., Stool E., Jemsek J.G., Dellamonica P., Cross A., and Dunkle L. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. Ann. Intern. Med. 126 (1997) 355-363
58. Starrett Jr. J.E., Tortolani D.R., Baker D.C., Omar M.T., Hebbler A.K., Wos J.A., Martin J.C., and Mansuri M.M. The use of acetyl bromide for the multigram synthesis of the anti-HIV agent 2′,3′-didehydro-2′,3′-dideoxycytidine (d4C). Nucleosides Nucleotides 9 (1990) 885-897
59. Sterzycki R., Mansuri M., Brankovan V., Buroker R., Ghazzouli I., Hitchcock M., Sommadossi J.-P., and Martin J.C. 1-(2,3-Dideoxy-3-fluoro-beta-d-ribofuranosyl)thymine (FddT): improved preparation and evaluation as a potential anti-AIDS agent. Nucleosides Nucleotides 8 (1989) 1115-1117
60. Webb II R.R., Wos J.A., Martin J.C., and Brodfuehrer P.R. Synthesis of 2′,3′-dideoxyinosine. Nucleosides Nucleotides 7 (1988) 147-153
61. Yarchoan R., Thomas R.V., Allain J.-P., McAtee N., Dubinsky R., Mitsuya H., Lawley T.J., Safai B., Myers C.E., Perno C.F., Klecker R.W., Wills R.J., Fischl M.A., McNeely M.C., Pluda J.M., Leuther M., Collins J.M., and Broder S. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet (1988) 76-81
62. Zhu Z., Ho H.-T., Hitchcock M.J., and Sommadossi J.-P. Cellular pharmacology of 2′,3′-didehydro-2′,3′-dideoxythymidine (D4T) in human peripheral blood mononuclear cells. Biochem. Pharmacol. 39 (1990) R15-R19